CFO/COO and director Christopher Lowe resigns; June Bray appointed director; Monohon named PFO
Quince Therapeutics, Inc.
Christopher Lowe resigned as board member (June 8) and as CFO/COO (effective June 10); separation includes $354,750 cash severance and equity acceleration.
June Bray appointed as Class III director; receives initial option for 54,000 shares at $3.20, vesting over 3 years.
Ted Monohon, current CAO and VP Finance, designated as principal financial officer; no change in compensation.
Sublease with ICON Clinical Research for 601 Gateway Blvd, SF: term June 18, 2022 to Nov 30, 2023, optional extension; rent $16,692-$17,206/mo.
Annual meeting: elected Lowe and Senner as directors, ratified BDO as auditor, approved say-on-pay.
Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).
Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).
On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the “Board”) of the Company, resigned as a member of the Board, effective immediately.
On June 9, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed June Bray to serve as a Class III director of the Company, effective immediately
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Christopher Lowe resigned as Chief Financial Officer at Quince Therapeutics, Inc..
Action
resigned
Role
Chief Financial Officer
Exact text from the filing
Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).
Christopher Lowe resigned as Chief Operating Officer at Quince Therapeutics, Inc..
Action
resigned
Role
Chief Operating Officer
Exact text from the filing
Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).
Christopher Lowe resigned as member of the Board of Directors at Quince Therapeutics, Inc..
Action
resigned
Role
member of the Board of Directors
Exact text from the filing
On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the “Board”) of the Company, resigned as a member of the Board, effective immediately.
June Bray was appointed as Class III director at Quince Therapeutics, Inc..
Action
appointed
Role
Class III director
Exact text from the filing
On June 9, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed June Bray to serve as a Class III director of the Company, effective immediately
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.